Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3436 | SARS-CoV-2 rS/Matrix M1-Adjuvant Wiki | 1.00 |
| drug4744 | standard care Wiki | 0.50 |
| drug2365 | Methylprednisolone Wiki | 0.27 |
Navigate: Correlations HPO
There is one clinical trial.
This is a study to evaluate the effectiveness, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom. A vaccine causes the body to have an immune response that may help prevent the infection or reduce the severity of symptoms. An adjuvant is something that can make a vaccine work better. This study will look at the protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1 adjuvant in the study population. Participants in the study will randomly be assigned to receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will receive a total of 2 intramuscular injections over the course of the study. Approximately 9,000 participants will take part in the study. The first 400 participants who meet additional criteria will receive a flu vaccine, in addition to the SARS-CoV-2 rS vaccine or placebo, as part of a sub-study. An effort will be made to enroll a target of at least 25% of participants who are ≥ 65 years of age, as well as prioritizing other groups that are most affected by COVID-19, including racial and ethnic minorities.
Description: Number of participants, testing serologically negative for SARS-CoV-2 at baseline, with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic COVID-19 with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Symptomatic COVID-19 Time: From Day 28 to Day 386Description: Number of participants, testing serologically negative for SARS-CoV-2 at baseline with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic moderate or severe COVID-19 with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Symptomatic Moderate or Severe COVID-19 Time: From Day 28 to Day 386Description: Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic COVID-19 assessed from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Symptomatic COVID-19 Time: From Day 28 to Day 386Description: Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, or serologically confirmed, SARS-CoV-2 illness with asymptomatic or symptomatic COVID-19 with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Asymptomatic or Symptomatic COVID-19 Time: From Day 28 to Day 386Description: Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with COVID-19 with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with COVID-19 requiring Hospitalization, Intensive Care Unit (ICU), or Mechanical Ventilation Time: From Day 28 to Day 386Description: Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild COVID-19 (with no progression to moderate or severe COVID-19 during the course of the COVID-19 episode) with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Symptomatic Mild COVID-19 Time: From Day 28 to Day 386Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMEUs (Geometric mean ELISA unit) at Day 0 (baseline), Day 21 (21 days after first study vaccination), and Day 35 (14 days after second study vaccination).
Measure: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMEUs Time: Day 0 to Day 35Description: Numbers and percentages (with 95% CI) of participants with SAEs (Serious Adverse Events) and MAAEs (Medically Attended Adverse Events) through End of Study by MedDRA classification, severity score and relatedness.
Measure: Participants with SAEs and MAAEs Time: 386 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports